Stavanger University Hospital Inflammatory Bowel Disease Trial (SUSI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01551563|
Recruitment Status : Recruiting
First Posted : March 12, 2012
Last Update Posted : December 5, 2017
The study aims at studying the outcomes of a protocol-based handling of newly diagnosed Inflammatory bowel disease ( IBD ) patients within a defined uptake area in Norway. It is a descriptive study and no hypothesis is predefined.
Cytokine studies, QoL and fatigue assessment will be included for hypothesis-generating purposes.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Management of Inflammatory Bowel Disease in the Stavanger Area - a Prospective Evaluation of Standardized Treatment Regimens on Disease Outcome With Focus on Mucosal Healing and Associations to Fatigue|
|Study Start Date :||April 2012|
|Estimated Primary Completion Date :||August 2018|
|Estimated Study Completion Date :||December 2023|
- Clinical efficacy of IBD drug therapy [ Time Frame: 5 years ]Endoscopic, clinical and biochemical response
- Fatigue in patients with coeliac disease - substudy [ Time Frame: 1 year ]Fatigue at diagnosis and after one year of gluten free diet
- Fatigue in IBD [ Time Frame: 5 years ]Fatigue at diagnosis and during follow-up
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01551563
|Contact: Tore B Grimstad, MD PhD +47909 21 650|
|Principal Investigator:||lars Aabakken||prof of medicine UIO|